Comparison of Bosutinib To Imatinib In Subjects With Newly Diagnosed Chronic Phase Philadelphia Chromosome Positive CML
- Registry ID
- EUCTR2007-003780-50
- Source registry
- EUCTR
- Status
- Completed
- Phase
- PHASE3
- Sponsor
- Wyeth Pharmaceuticals Inc, a wholly owned subsidiary of Pfizer Inc, 500 Arcola Road, Collegeville, PA 19426 USA
- Start date
- 2008-04-04
- Completion date
- 2015-05-25
- Last update
- 2026-08-16
Conditions
- Chronic myelogenous leukemia (CML)
- Leucemia mieloide crónica (LMC) Chronic myelogenous leukemia (CML)
Summary
Compare the rate of complete cytogenetic response (CCyR) at one year in chronic phase subjects receiving bosutinib alone versus chronic phase subjects receiving imatinib alone.
Locations
- , , Lithuania
- , , Hungary
- , , Belgium
- , , France
- , , Slovenia
- , , UK
- , , Italy
- , , Latvia
- , , Spain
- , , Germany
View on source registry